title: [Mode of action, clinical profile and relevance of carbonic                     anhydrase inhibitors in glaucoma therapy].
abstract: Since their introduction the local carbonic anhydrase inhibitors (CAH)                         dorzolamide and brinzolamide have become well established in the drug                         therapy of glaucoma. They lower intraocular pressure (IOP) by blocking                         specifically carbonic anhydrase in the ciliary epithelium and thereby the                         secretion of aqueous humor. The IOP lowering effect is comparable with that                         of beta-blockers, but less than that of prostaglandin agonists. Because of                         their specific mode of action they produce an additive pressure lowering                         effect with any other glaucoma drug. Therefore they are ideal for being                         combined with other drugs. In addition, CAH may improve perfusion of the                         posterior eye. Preliminary results in glaucoma patients under dorzolamide                         therapy suggesting a reduction in the risk of progression due to enhanced                         blood flow need further confirmation.
authors: Institut für Anatomie - LS II, Universität Erlangen-Nürnberg, Universitätsstrasse 19, Erlangen. michael.eichhorn@fau.de
authors: M
authors: M
authors: Eichhorn
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002924:Ciliary Body / Q000187:drug effects / Q000503:physiopathology; D004338:Drug Combinations; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects* / Q000502:physiology; D009883:Ophthalmic Solutions; D012171:Retinal Vessels / Q000187:drug effects / Q000503:physiopathology; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D013843:Thiazines / Q000009:adverse effects / Q000627:therapeutic use*; D013876:Thiophenes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013843:Thiazines; D013876:Thiophenes; C111827:brinzolamide; C062765:dorzolamide